# Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.

> **NCT00313001** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 373 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** biphasic insulin aspart
- **DRUG:** exenatide

## Key facts

- **NCT ID:** NCT00313001
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 373 (ACTUAL)
- **Last updated:** 2017-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00313001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00313001, "Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00313001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*